CEACAM6抗体;CEACAM6 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CEACAM6 mouse mAb against Jurkat (1), PC-12 (2), HEK293 (3), MG63 (4), and C2C12 (5) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CEACAM6 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CEACAM6 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colon tissues using CEACAM6 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using CEACAM6 mouse mAb with DAB staining.    

  
  

**Background of CEACAM6 Antibodies**

CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein belonging to the CEACAM family, which plays roles in cell adhesion, signaling, and immune regulation. It is typically expressed at low levels in normal tissues but is overexpressed in various cancers, including pancreatic, colorectal, breast, and lung adenocarcinomas. This upregulation correlates with tumor progression, metastasis, and resistance to therapy, making CEACAM6 a potential diagnostic and therapeutic target.

CEACAM6 antibodies are immunological tools designed to specifically bind to CEACAM6 epitopes. Monoclonal and polyclonal variants are widely used in research to detect CEACAM6 expression via techniques like immunohistochemistry, flow cytometry, and Western blot. These antibodies help elucidate CEACAM6's role in cancer biology, including its involvement in inhibiting apoptosis, promoting invasion, and modulating immune evasion.

Therapeutically, CEACAM6-targeting antibodies are explored in preclinical and clinical studies for their ability to deliver cytotoxic agents or engage immune cells against tumors. Challenges include ensuring specificity to avoid off-target effects, given CEACAM6's limited expression in healthy tissues. Nonetheless, its prominence in malignancies positions CEACAM6 antibodies as promising candidates for biomarker-driven oncology therapies and precision medicine applications.